open access

Vol 70, No 3 (2020)
Original article
Published online: 2020-06-16
Get Citation

The prognostic significance of HLA-A2 expression on somatic cells in patients with left-sided colon and rectal cancers

Katarzyna Dyląg-Trojanowska, Radosław Pach, Maciej Siedlar, Jarosław Baran, Justyna Zybaczynska, Antoni M. Szczepanik
DOI: 10.5603/NJO.2020.0020
·
Nowotwory. Journal of Oncology 2020;70(3):92-97.

open access

Vol 70, No 3 (2020)
Original article
Published online: 2020-06-16

Abstract

Introduction. Current knowledge about colorectal cancer (CRC) identifies tumor immunogenicity as one of the more important issues. In cancers, a prerequisite for immune system activation is the presentation of tumor associated antigen (TAA) epitopes to immunocompetent cells. HLA-A2 is one of the antigens in the context of which TAAs are present, but data on the possible impact of HLA-A2 antigen expression on the survival of patients with colorectal cancer are scarce and sometimes contradictory. The aim of this study was to analyse the relationship between HLA-A2 expression in patients with left-sided colorectal cancer in various stages of disease and their long-term survival, and to answer the question of whether a lack of HLA-A2 expression is actually a negative prognostic factor.

Material and methods.  A prospective analysis of 58 patients with left-sided colorectal cancer was carried out. Expression of HLA-A2 was determined by patient blood lymphocyte staining, and analysed using flow cytometry.

Results. In the study group, patients with HLA-A2 expression lived statistically longer than HLA-A2 negative patients (p = 0.027). There was no significant difference in overall survival between the HLA-A2+ and HLA-A2- groups with stage II and III left-sided CRC. However, the Cox proportional hazard model showed that a lack of HLA-A2 expression was a negative prognostic factor in the group of radically operated patients without distant metastases.

Conclusions. HLA-A2 status may affect the clinical course of patients with left-sided colon and rectal cancer, although left-sided tumors are less immunogenic than right-sided ones. HLA-A2-positive patients with left-sided colorectal cancer lived statistically longer than those who were HLA-A2-negative (p = 0.027). Lack of HLA-A2 expression was a negative prognostic factor in the group of radically operated patients.

Abstract

Introduction. Current knowledge about colorectal cancer (CRC) identifies tumor immunogenicity as one of the more important issues. In cancers, a prerequisite for immune system activation is the presentation of tumor associated antigen (TAA) epitopes to immunocompetent cells. HLA-A2 is one of the antigens in the context of which TAAs are present, but data on the possible impact of HLA-A2 antigen expression on the survival of patients with colorectal cancer are scarce and sometimes contradictory. The aim of this study was to analyse the relationship between HLA-A2 expression in patients with left-sided colorectal cancer in various stages of disease and their long-term survival, and to answer the question of whether a lack of HLA-A2 expression is actually a negative prognostic factor.

Material and methods.  A prospective analysis of 58 patients with left-sided colorectal cancer was carried out. Expression of HLA-A2 was determined by patient blood lymphocyte staining, and analysed using flow cytometry.

Results. In the study group, patients with HLA-A2 expression lived statistically longer than HLA-A2 negative patients (p = 0.027). There was no significant difference in overall survival between the HLA-A2+ and HLA-A2- groups with stage II and III left-sided CRC. However, the Cox proportional hazard model showed that a lack of HLA-A2 expression was a negative prognostic factor in the group of radically operated patients without distant metastases.

Conclusions. HLA-A2 status may affect the clinical course of patients with left-sided colon and rectal cancer, although left-sided tumors are less immunogenic than right-sided ones. HLA-A2-positive patients with left-sided colorectal cancer lived statistically longer than those who were HLA-A2-negative (p = 0.027). Lack of HLA-A2 expression was a negative prognostic factor in the group of radically operated patients.

Get Citation

Keywords

HLA; HLA-A2; left-sided colon cancer; overall survival; prognostic biomarker

About this article
Title

The prognostic significance of HLA-A2 expression on somatic cells in patients with left-sided colon and rectal cancers

Journal

Nowotwory. Journal of Oncology

Issue

Vol 70, No 3 (2020)

Pages

92-97

Published online

2020-06-16

DOI

10.5603/NJO.2020.0020

Bibliographic record

Nowotwory. Journal of Oncology 2020;70(3):92-97.

Keywords

HLA
HLA-A2
left-sided colon cancer
overall survival
prognostic biomarker

Authors

Katarzyna Dyląg-Trojanowska
Radosław Pach
Maciej Siedlar
Jarosław Baran
Justyna Zybaczynska
Antoni M. Szczepanik

References (30)
  1. Pandolfi F, Boyle LA, Trentin L, et al. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 1991; 51(12): 3164–3170.
  2. Kiewe P, Mansmann V, Scheibenbogen C, et al. HLA-A2 expression, stage, and survival in colorectal cancer. Int J Colorectal Dis. 2008; 23(8): 767–772.
  3. Hee Lee Ji, Park MS, Hwang JE, et al. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. Cell Mol Immunol. 2013; 10(3): 275–282.
  4. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005; 33(2): 113–133.
  5. Madjd Z, Spendlove I, Pinder SE, et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005; 117(2): 248–255.
  6. Vitale M, Pelusi G, Taroni B, et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005; 11(1): 67–72.
  7. Gamzatova Z, Villabona L, Dahlgren L, et al. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol. 2006; 103(1): 145–150.
  8. De Petris L, Bergfeldt K, Hising C, et al. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol. 2004; 21(1): 49–52.
  9. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006; 66(18): 9281–9289.
  10. Mezquita L, Charrier M, Faivre L, et al. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017; 112: 10–15.
  11. Dierssen JW, de Miranda NF, Mulder A, et al. High-resolution analysis of HLA class I alterations in colorectal cancer. BMC Cancer. 2006; 6: 233.
  12. Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 2005; 65(14): 6418–6424.
  13. Söreide K, Janssen EAM, Söiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg. 2006; 93(4): 395–406.
  14. Kim K, Castro EJ, Shim H, et al. Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer. Ann Coloproctol. 2018; 34(6): 280–285.
  15. Speetjens FM, de Bruin EC, Morreau H, et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother. 2008; 57(5): 601–609.
  16. Passardi A, Canale M, Valgiusti M, et al. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017; 18(6).
  17. Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017; 27(1): 11–37.
  18. Lim DRo, Kuk JK, Kim T, et al. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine (Baltimore). 2017; 96(42): e8241.
  19. Benedix F, Kube R, Meyer F, et al. Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010; 53(1): 57–64.
  20. Derwinger K, Gustavsson B. Variations in demography and prognosis by colon cancer location. Anticancer Res. 2011; 31(6): 2347–2350.
  21. Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015; 21(21): 6470–6478.
  22. de Vries NL, Swets M, Vahrmeijer AL, et al. The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci. 2016; 17(7).
  23. Löffler MW, Kowalewski DJ, Backert L, et al. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Res. 2018; 78(16): 4627–4641.
  24. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350–1356.
  25. Sandel MH, Speetjens FM, Menon AG, et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol. 2005; 42(4): 541–546.
  26. Swets M, König MH, Zaalberg A, et al. HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. Hum Immunol. 2016; 77(9): 773–779.
  27. Zeestraten ECM, Reimers MS, Saadatmand S, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014; 110(2): 459–468.
  28. Reimers MS, Engels CC, Putter H, et al. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer. 2014; 14: 486.
  29. Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer. 2010; 127(5): 1001–1010.
  30. Ijsselsteijn ME, Petitprez F, Lacroix L, et al. Revisiting immune escape in colorectal cancer in the era of immunotherapy. Br J Cancer. 2019; 120(8): 815–818.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl